Status:

UNKNOWN

Lymphadenectomy in NSCLC With and Without Adjuvant Therapy

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions:

NSCLC

Lymph Node Metastases

Eligibility:

All Genders

18+ years

Brief Summary

Adjuvant therapy in patients affected by NSCLC is indicated in surgically treated cases of N2 disease, while the actual guidelines reported the possibility of a case-by-case decision in case of N1 inv...

Eligibility Criteria

Inclusion

  • Informed consent
  • Age \>18 years
  • Non-Small Cell Lung Cancer Histology
  • Anatomical lung resection (segmentectomy, lobectomy or bilobectomy, pneumonectomy)
  • Pre-operative CT and PET evaluation
  • Preoperative and postoperative tumour board discussion
  • Intraoperative lymph node assessment (minimum 3 mediastinal stations harvested)
  • Lymph node metastases

Exclusion

  • AGE \< 18 years
  • Pregnancy
  • Psychiatric disease
  • Wedge resection
  • Distant metastases

Key Trial Info

Start Date :

May 13 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 1 2025

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT04419935

Start Date

May 13 2020

End Date

May 1 2025

Last Update

June 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Marco Chiappetta

Roma, Italy, 00168